Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | FBP1 | P09467 | 13/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706529 | 0.85 | POLB (0.46) | POLBFBP1KMT2AHPGDRAB9A | |
| SCHEMBL1706644 | 0.83 | POLB (0.42) | POLBFBP1HPGDRAB9A | |
| SCHEMBL2818296 | 0.76 | POLB (0.55) | POLBKMT2AHPGDRAB9A | |
| SCHEMBL1706768 | 0.73 | POLB (0.49) | POLBKMT2AHPGDRAB9A | |
| SCHEMBL7509196 | 0.73 | GAA (0.65) | FBP1KMT2AHPGDRAB9AHCRTR2 | |
| SCHEMBL4662276 | 0.73 | KMT2A (0.49) | FBP1KMT2AHPGDHCRTR2HIF1A | |
| SCHEMBL2820268 | 0.72 | HPGD (0.62) | POLBKMT2AHPGDRAB9APKM | |
| SCHEMBL30986723 | 0.72 | FBP1 (0.59) | FBP1KMT2AHPGDHIF1A | |
| SCHEMBL14495875 | 0.71 | POLB (0.50) | POLBKMT2AHPGDRAB9A | |
| SCHEMBL12390716 | 0.71 | POLB (0.50) | POLBKMT2AHPGDRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2247579-B1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | Bayer Pharma AG (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| US-7863283-B2 | Sulphoximine-substituted quinazoline derivatives as immuno-modulators, their preparation and use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2011-01-04 | — | — | US | disclosed |
| EP-2247579-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009089851-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-23 | — | — | WO | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| WO-2009089851-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNOMODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-07-23 | — | — | WO | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186911-A1 | SULPHOXIMINE-SUBSTITUTED QUINAZOLINE DERIVATIVES AS IMMUNO-MODULATORS, THEIR PREPARATION AND USE AS MEDICAMENTS | IFNG, TPMT, IRF3 | POLB 2252/4885FBP1 746/4885KMT2A 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.